Organon & Co. Price Today
Organon & Co.
OGN
Healthcare
$5.49B
๐ฐ
Market Cap
7.3
๐ธ
Price to Earnings
$3.0
๐
EPS
+0
๐ณ
ESG
Consensus Recommendations
Hold Consensus
Buy |
6 |
Strong Buy |
1 |
Hold |
5 |
Sell |
1 |
Strong Sell |
0 |
OGN Price Forecast Target
21.5 ๐ 43.0 +100%
OGN EPS Forecast
3.0 ๐ 4.6 +56%
Financials
Profit Margin
12 %
Revenue Growth
-1.9 %
Dividend
$ 1.12
Held Percent
0.1% - Insiders
79.8% - Institutions
20.1% - Public
Major Fund Holders
-
๐ฐ Vanguard Group Inc $745.0M
-
๐ฐ Blackrock Inc. $381.7M
-
๐ฐ Mawer Investment Management Ltd. $312.2M
-
๐ฐ State Street Corporation $301.8M
-
๐ฐ Massachusetts Financial Services Co. $196.7M
Stock Ideas
Bill Ackman Portfolio
Bill Ackman, a renowned investor, has established himself as a long-term value investor with a keen eye for short-term price fluctuations. His expertise lies in special situations investments, and his Pershing Square portfolio reflects a highly concโฆCharlie Munger Portfolio
Charlie Munger, the renowned investor and Vice Chairman of Berkshire Hathaway, is a true titan in the world of finance. Often referred to as Warren Buffett's right-hand man, Munger's portfolio investment approach is a masterclass in disciplined and โฆJim Chanos Portfolio
Jim Chanos is a revered figure in the world of portfolio management, known for his expertise in short selling and his pivotal role in uncovering fraud at Enron and WorldCom. Hailing from Milwaukee and a graduate of Yale with an economics degree, ChโฆStephen Mandel Portfolio
Stephen Mandel is the founder and portfolio manager of Lone Pine Capital, one of the largest and most successful hedge funds. Employing rigorous fundamental analysis, Mandel searches globally for qualitatively excellent growth companies trading at rโฆ๐ฎFAQ
Some Frequently Asked Questions.
The Organon & Co. industry is Drug ManufacturersโGeneral
The Organon & Co. sector is Healthcare
The Organon & Co. forecasted predicted Price to Earnings PE ratio is 4.7
The Organon & Co. Price to Earnings PE ratio is 7.3
The Market Capitalization of Organon & Co. is $5.49B
There are total of 254689357 float shares with 79.8% held by Institutions and 0.1% held by insiders
The MOrganon & Co. forecasted Earnings per Share EPS is $4.6
The Organon & Co. Earnings per Share EPS is 3.0
The Organon & Co. company has $3889000000 gross profits with 12 profit margins
The Organon & Co. Earnings Growth is -0.493% with -0.491% quarterly earnings growth
The Organon & Co. Revenue is $6144999936 with -0.019 revenue growth
The price target for Organon & Co. stock is $43.0 for the high target and $23.0 for the low target
The consensus analyst recommendations for Organon & Co. is Hold, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Organon & Co. is Hold, with the following breakdown:
- Buy: 6
- Strong Buy: 1
- Hold: 5
- Sell: 1
- Strong Sell: 0
The Beta of Organon & Co. is 0.8
The dividend of Organon & Co. is $1.12
The dividend yield of Organon & Co. is 0.051999997%
The biggest institutional and mutual fund holders of Organon & Co. stock are
- Vanguard Group Inc
- Blackrock Inc.
- Mawer Investment Management Ltd.
- State Street Corporation
The Organon & Co. ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0